Open AccessBcl‐2, B cl‐6, and the I nternational P rognostic I ndex are prognostic indicators in patients with diffuse large B ‐cell lymphoma treated with rituximab‐containing chemotherapy
Author(s) -
Maeshima Akiko Miyagi,
Taniguchi Hirokazu,
Fukuhara Suguru,
Morikawa Noriyuki,
Munakata Wataru,
Maruyama Dai,
Kim SungWon,
Watanabe Takashi,
Kobayashi Yukio,
Tobinai Kensei,
Tsuda Hitoshi
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2012.02382.x
Subject(s) - chemistry
This study aimed to clarify the clinicopathological prognostic parameters of de novo diffuse large B ‐cell lymphoma ( DLBCL ) in the rituximab era. We examined the correlation of 22 clinicopathological parameters with progression‐free survival ( PFS ), overall survival ( OS ), and primary refractory disease in 285 DLBCL patients treated with rituximab‐containing chemotherapy. Complete response rate was 87%, overall response rate was 91%, 5‐year PFS rate was 72%, and 5‐year OS rate was 91%. By log–rank test, higher I nternational P rognostic I ndex ( IPI ) ( P < 0.0001), B cl‐2 positivity ( P = 0.0013), B cl‐6 negativity ( P = 0.0112), and no irradiation ( P = 0.0371) were significantly correlated with shorter PFS ; higher IPI ( P = 0.0107), starry sky pattern ( P = 0.0466), and no irradiation ( P = 0.0264) correlated with shorter OS . In multivariate analyses, higher IPI ( P = 0.0006), B cl‐2 positivity ( P = 0.0015), and B cl‐6 negativity ( P = 0.04) were significantly correlated with shorter PFS ; higher IPI ( P = 0.0045) correlated with shorter OS . Bcl‐2 ( P = 0.0029), B cl‐6 ( P = 0.002), and IPI ( P < 0.0001) were significantly correlated with primary refractory disease. In conclusion, B cl‐2 positivity, B cl‐6 negativity, and higher IPI were indicators of shorter PFS and OS plus primary refractory disease in patients with DLBCL in the rituximab era.